- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
Authors
Keywords
-
Journal
Dermatology and Therapy
Volume 10, Issue 1, Pages 29-42
Publisher
Springer Science and Business Media LLC
Online
2019-12-31
DOI
10.1007/s13555-019-00347-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)
- (2019) Xingrui He et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
- (2019) Laura M. Sawyer et al. PLoS One
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- (2019) Kata P. Szilveszter et al. Frontiers in Immunology
- Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
- (2018) A. Egeberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment
- (2018) Jaehwan Kim et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials
- (2018) B.E. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic alterations driving psoriasis pathogenesis
- (2018) S. Singh et al. GENE
- Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients
- (2018) Rishi J. Desai et al. Arthritis & Rheumatology
- Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis
- (2017) Robert Wolk et al. Journal of Clinical Lipidology
- The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
- (2017) JianZhong Zhang et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Herpes zoster in psoriasis patients treated with tofacitinib
- (2017) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
- (2016) Robert Bissonnette et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
- (2016) Christina Charles-Schoeman et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
- (2015) N. Punwani et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2015) Richard B. Warren et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- PASI90 response: the new standard in therapeutic efficacy for psoriasis
- (2014) L. Puig JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
- (2014) Leeyen Hsu et al. Journal of Immunology Research
- Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
- (2013) B. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Tyk2 is a therapeutic target for psoriasis-like skin inflammation
- (2013) M. Ishizaki et al. INTERNATIONAL IMMUNOLOGY
- Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis
- (2013) Eleanor J. Samarasekera et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study
- (2010) O. Ahlehoff et al. JOURNAL OF INTERNAL MEDICINE
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More